Abstract
The use of synthetic peptides for the development of new drugs is a promising strategy in the fields of biotechnology. Peptides derived from intracellular bacterial toxins produced by systems of the post-segregational killer (PKS) such as CcdB is an example of this strategy. However, drugs with peptide structures derived from bacterial toxins present serious problems in therapeutic applic…